Related by context. All words. (Click for frequent words.) 71 underwent resection 70 underwent CABG 70 relapsed MM 70 stage IIIb IV 68 antiretroviral naïve 68 underwent surgical resection 68 nondiabetic patients 68 de novo kidney transplant 68 recurrent glioblastoma multiforme 67 allogeneic hematopoietic stem cell 67 operable breast cancer 67 prior chemotherapy regimens 67 treatment naïve genotype 67 histologically confirmed 67 hepatorenal syndrome 66 posttransplant 66 biochemical relapse 66 KRAS mutations occur 66 prospectively enrolled 66 retrospective cohort 66 thrombocytopenic 65 randomized multicenter trial 65 treatment naive genotype 65 aged ≥ 65 neurologic progression 65 weekly intravenous infusions 65 evaluable subjects 65 CR nPR 65 undetectable HBV DNA 65 stage IIIB IV 65 % CI #.#-#.# [003] 65 undergone radical prostatectomy 65 refractory myeloma 65 HSCT 64 IV NSCLC 64 HIV HCV coinfected 64 de novo AML 64 papillary renal cell carcinoma 64 systemic ALCL 64 acute myeloid 64 relapsed AML 64 receiving VICTRELIS 64 underwent radical cystectomy 64 achieved ACR# 64 FOLFOX4 64 clinically localized prostate 64 visceral metastases 64 underwent radical prostatectomy 64 pretransplant 64 antiretroviral naive 64 stage IIIb 64 dose escalation phase 64 #mg ATC 64 Flu Cy 64 hemodialysis patients 64 pancreatic resection 64 pancreatic adenocarcinoma 63 infliximab monotherapy 63 nadroparin 63 metastatic lung cancer 63 rFVIIa 63 liver transplant recipients 63 leukemia AML 63 Kaplan Meier estimate 63 nonmetastatic 63 mitoxantrone plus 63 mg/m2 dose 63 preintervention 63 dosing cohort 63 CIMZIA TM certolizumab pegol 63 interquartile range 63 adjunctive placebo 63 iniparib BSI 63 adjuvant tamoxifen 63 galiximab 63 anagrelide 63 perioperatively 63 euthyroid 63 NATRECOR R 63 liver histology 63 T1c 63 untreated AML 63 decompensated liver disease 63 refractory CLL 63 Doxil ® 63 ß blockers 63 achieved CCyR 63 mg administered orally 63 mcg BID 63 allogeneic transplants 62 pamidronate 62 daily subcutaneous injections 62 NATRECOR ® 62 Myelodysplastic Syndrome MDS 62 nulliparous women 62 weekly subcutaneous injections 62 BARACLUDE ® 62 nonischemic 62 HBeAg negative patients 62 comparator arm 62 chemoradiation therapy 62 autoantibody positive 62 anthracycline taxane 62 chronic HCV genotype 62 NMIBC 62 5-fluorouracil/leucovorin 62 achieved sustained virological 62 liver resection 62 undergone splenectomy 62 hypercholesterolemic patients 62 ischemic cardiomyopathy 62 IFN alfa 62 allogeneic HSCT 62 non splenectomized 62 chronic GVHD 62 mcg albinterferon alfa 2b 62 PLX STROKE targeting 62 CC genotype 62 relapsing remitting MS RRMS 62 renal transplants 62 seropositivity 62 induced anemia 62 HIV coinfected 62 total abdominal hysterectomy 62 Multicenter AIDS 62 medically inoperable 62 Subgroup analysis 62 mutated K ras 62 azilsartan medoxomil 62 squamous histology 62 mg/m2 IV 62 clot busting therapy 62 thrombocytopenic patients 62 undergoing CABG 62 #mg dosing group 62 Heterozygous Familial Hypercholesterolemia 62 systolic dysfunction 62 allogeneic transplant 62 baseline Hb 62 heFH 61 metastatic GIST 61 myelodysplastic myeloproliferative diseases 61 placebo dexamethasone 61 CRp 61 patients undergoing CABG 61 glycated hemoglobin levels 61 Arch Intern Med 61 recurrent VTE 61 interferon ribavirin 61 pT3 61 low dose Iluvien 61 8mg/kg 61 basiliximab 61 autologous transplants 61 baseline PASI 61 HIV seronegative 61 heavily pretreated 61 preoperative chemotherapy 61 Ishak fibrosis score 61 multicenter randomized controlled 61 metastatic CRPC 61 CYPHER Stent 61 mCRC patients 61 resected pancreatic cancer 61 prospectively evaluated 61 lenalidomide Revlimid R 61 octreotide LAR 61 intravenous RSD# 61 bortezomib refractory 61 type 1diabetes 61 NNT = 61 intravenous bolus 61 Engerix B 61 hepatic resection 61 venlafaxine XR 61 null responder HCV 61 CCyR 61 underwent percutaneous coronary 61 deep venous thromboses 61 lipid lowering therapy 61 genotypic resistance 61 tipranavir r 61 mRCC 61 rituximab refractory 61 flutamide 61 smoldering myeloma 61 mL/min/#.# m 2 61 smoldering multiple myeloma 61 detectable HCV RNA 61 asymptomatic metastatic 61 cis retinoic acid 61 advanced epithelial ovarian 61 dose melphalan 61 ER CHOP 61 cytoreduction 61 intravenous cyclophosphamide 61 colorectal cancer liver metastases 61 ALN VSP Phase 61 decompensated heart failure 61 endoscopic remission 61 Median survival 61 refractory acute myeloid 61 blinded randomized placebo controlled 61 chlorambucil 61 calcineurin inhibitor 61 #mg BID [001] 61 ejection fractions 61 argatroban 61 beta blocker therapy 61 mutated KRAS 61 undergoing hematopoietic stem 61 lymphocytosis 61 MELD scores 61 Decompensated Heart Failure 61 underwent bariatric surgery 61 pouchitis 61 postoperative chemotherapy 61 mycophenolate mofetil MMF 61 Cell Lymphoma CTCL 61 mild renal insufficiency 61 Acute Myeloid Leukaemia AML 61 recurrent glioma 61 Adjuvant therapy 61 abdominal irradiation 61 PROSTVAC VF 61 severe neutropenia 61 randomized blinded 61 EGFR mutation positive 61 unresectable stage 60 rt PA 60 receiving highly emetogenic 60 REYATAZ r arm 60 HCV SPRINT 60 graft occlusion 60 selective phosphodiesterase 60 bladder carcinoma 60 MAGE A3 ASCI 60 previously untreated follicular 60 MGd 60 KRAS mutant tumors 60 bowel resection 60 renal transplantation 60 pancreatic carcinoma 60 refractory metastatic 60 primary immunodeficiency PI 60 decompensated cirrhosis 60 metastatic hormone refractory 60 Waldenstrom macroglobulinemia 60 INSPIRE Trial Phase III 60 oral clodronate 60 postintervention 60 paricalcitol 60 reduce serum phosphate 60 allogenic stem cell 60 dacarbazine chemotherapy 60 relapsed GBM 60 humanised monoclonal antibody 60 transplantation HCT 60 refractory colorectal cancer 60 peginterferon alpha 2a 60 antithymocyte globulin 60 unresectable HCC 60 symptomatic BPH 60 lymphocytic leukemia 60 nutlin 3a 60 MADIT II 60 nucleoside naive 60 HBeAg negative 60 dose dose escalation 60 % CI #.#-#.# [008] 60 eosinophilic asthma 60 abacavir lamivudine 60 undetectable virus HCV 60 elevated ALT 60 hepatectomy 60 CIMZIA TM 60 Folfox 60 pediatric acute lymphoblastic 60 metastatic renal cell 60 relapsed refractory AML 60 radioiodine therapy 60 anthracycline therapy 60 Zemplar Capsules 60 FluCAM arm 60 undetectable viral 60 autologous hematopoietic stem cell 60 histologically proven 60 preoperative PSA 60 paclitaxel cisplatin 60 metastatic gastric 60 retrospectively analyzed 60 advanced medullary thyroid 60 bone marrow reticulin deposition 60 allogeneic stem cell 60 fluvastatin 60 induce remission 60 #mg QD [001] 60 steroid refractory 60 haematopoietic stem cell 60 unresectable tumors 60 progression TTP 60 untreated CLL 60 GnRH agonist 60 portal vein thrombosis 60 CLL SLL 60 perioperative complications 60 #mg dose [002] 60 retransplantation 60 adjuvant cisplatin 60 metastatic bladder 60 Temsirolimus 60 azacitidine 60 demonstrated antitumor activity 60 relapsing multiple sclerosis 60 serum urate levels 60 Adjuvant chemotherapy 60 morphometric vertebral fractures 60 carotid artery blockage 60 metastatic testicular cancer 60 #mg/day [001] 60 prospective nonrandomized 60 receiving antiretroviral therapy 60 clinically meaningful improvements 60 relapsed ALL 60 EOquin TM phase 60 Amrubicin 60 angiographic outcomes 60 PSA nadir 60 tinzaparin 60 adult chronic ITP 60 biliary tract cancer 60 prospectively stratified 60 retrospective cohort study 60 cisplatin chemotherapy 60 everolimus eluting stents 60 certolizumab 60 Erectile function 60 RRMS patients 60 lamivudine monotherapy 60 amoxicillin clavulanate 60 microgram kg 60 Ophena TM 60 timepoints 60 non CF bronchiectasis 60 unstable angina pectoris 60 Gliadel Wafer 60 sorafenib Nexavar 60 chorioamnionitis 60 recurrent GBM 60 prospective observational 60 biochemical recurrence 60 cranial irradiation 60 undergoing peritoneal dialysis 60 hepatitis C genotype 60 adalimumab Humira 60 aprepitant 60 methotrexate monotherapy 60 RECORD1 60 undergoing radical cystectomy 60 asymptomatic PAD 60 NYHA functional class 60 autologous transplant 60 subcutaneous enoxaparin 60 relapsed CLL 60 immune thrombocytopenic purpura ITP 60 clodronate 60 antiangiogenic therapy 60 trial evaluating Prochymal 60 anthracyclines taxanes 60 Tumors shrank 60 inhaled cyclosporine 59 intravenous diuretics 59 T1DM 59 FOLFIRI alone 59 cGy 59 Acute myeloid leukemia 59 CALGB # [002] 59 maximal doses 59 #mg QD [002] 59 ximelagatran 59 receiving ISENTRESS 59 Temodar ® 59 subcutaneous methylnaltrexone 59 corticosteroid dose 59 trastuzumab Herceptin ® 59 lintuzumab SGN 59 acute STEMI 59 HER2 positive metastatic breast 59 LHRH receptor positive 59 underwent angiography 59 HLA matched 59 myeloablative 59 HNSCC 59 prospective observational cohort 59 R abatacept 59 MVax R 59 bronchoalveolar lavage fluid 59 MMSE score 59 APTIVUS r 59 riociguat 59 intradermal injections 59 overt nephropathy 59 CMV disease 59 pancreatic islet cell 59 lanthanum carbonate 59 dosing cohorts 59 recurrent UTI 59 CLARITY study 59 multicentre prospective 59 taxane refractory 59 deletion 5q 59 remission CR 59 metastatic malignant melanoma 59 undergoing bariatric surgery 59 PPAR gamma agonist 59 monoclonal gammopathy 59 recurrent metastatic 59 stem cell engraftment 59 nephrectomy 59 Surgical resection 59 invasive aspergillosis 59 HBeAg positive patients 59 dalteparin 59 Glioblastoma Multiforme 59 postmenopausal osteoporotic women 59 ECOG PS 59 mg simvastatin 59 folinic acid 59 SHPT 59 complete cytogenetic response 59 elevated transaminases 59 multicenter Phase 59 ABSORB trial 59 OPT CHF 59 AIR2 Trial 59 rFSH 59 paroxysmal AF 59 esophagectomy 59 antirheumatic 59 thoracoscopic lobectomy 59 AML MDS 59 debulking surgery 59 ofpatients 59 malignant neoplasm 59 epoetin alpha 59 colorectal liver metastases 59 stage IIIB 59 pegylated interferon alpha 59 pelvic lymphadenectomy 59 renal cell carcinomas 59 severe exacerbations 59 Raptiva r 59 osteoporotic vertebral compression fractures 59 neurodevelopmental impairment 59 Hodgkin lymphoma HL 59 somatostatin analog 59 advanced adenoma 59 relapsed refractory multiple myeloma 59 tamoxifen therapy 59 BoNTA 59 COU AA 59 hepatocellular carcinomas 59 liver biopsies 59 total thyroidectomy 59 abacavir Ziagen 59 mg kg dose 59 Retreatment 59 underwent coronary angiography 59 histological subtype 59 RSR# efaproxiral 59 % CI #.#-#.# [007] 59 Hurler syndrome 59 prospectively randomized 59 Partial Responses 59 CALGB 59 placebo controlled clinical 59 Renal Cell Carcinoma RCC 59 fasting triglyceride levels 59 recurrent malignant glioma 59 dose cohort 59 chronic hemodialysis 59 Severe Primary IGFD 59 graft dysfunction 59 chemoradiotherapy 59 COPD exacerbation 59 adriamycin 59 lung metastases 59 PNH patients 59 genitourinary GU 59 mCRPC 59 HCV RESPOND 2 59 Xelox 59 VELCADE melphalan 59 Bezielle 59 Torisel 59 CHAMPION PCI 59 hematopoietic cancers 59 receiving immunosuppressive therapy 59 PREZISTA r 59 phase IIb study 59 Sprycel dasatinib 59 IMPACT DCM trial 59 TTF Therapy 59 hematological malignancy 59 buprenorphine implants 59 estramustine 59 oral Hycamtin 59 #mg/day [002] 59 unresectable recurrent 59 immunosuppression therapy 59 genotype 1a 59 tenecteplase 59 pomalidomide 59 IOP lowering 59 sustained virological response 59 visilizumab 59 oral rivaroxaban 59 locoregional recurrence 59 Index CDAI 59 null responder 59 refractory indolent non 59 CHOP chemotherapy 59 ipsilateral breast 59 NSTE ACS 59 observational cohort study 59 prospectively defined 59 neutropenic sepsis 59 basal cell nevus syndrome 59 RSD# oral 59 Myelodysplastic Syndrome 59 nonobese patients 59 multicenter Phase III 59 malignant pleural effusion 59 PEGINTRON TM 59 IV melanoma 59 Clinical Antipsychotic Trials 59 Azacitidine 59 adverse cytogenetics 59 titrated glipizide 59 Aryplase 59 subcutaneous PRO 59 haematologic malignancies 59 clinically evaluable 59 gemcitabine carboplatin 59 valsartan amlodipine 59 IEQ kg 59 GAMMAGARD 59 Nesiritide 59 hsCRP levels 59 BCG vaccinated 59 hepatic encephalopathy HE 59 patientswith 59 partial remissions 59 virologic failure 59 primary hypercholesterolemia 59 mycophenolate 59 anastrazole 59 HIV uninfected 59 Pemetrexed 58 docetaxel chemotherapy 58 metastatic HRPC 58 BEXXAR Therapeutic Regimen 58 intravenous morphine 58 haematologic 58 UKPDS 58 protease inhibitor PI 58 hours postdose 58 Cloretazine 58 BR.# 58 prostate carcinoma 58 Scale EDSS 58 DEB# 58 renal transplant 58 undergoing coronary artery 58 completely resected 58 ZACTIMA 58 nucleoside naive patients 58 placebo controlled dose escalation 58 aldosterone antagonist 58 HBV infections 58 plus prednisone 58 cART 58 ovarian carcinoma 58 recurrent atrial fibrillation 58 Postoperative complications 58 nadolol 58 Amgen Neulasta ® 58 macroalbuminuria 58 gefitinib Iressa 58 ASCEND HF 58 malignant ascites 58 metastatic malignant 58 5-FU/LV 58 q#h 58 naïve HCV 58 ELACYT 58 pediatric inpatients 58 Navelbine ® 58 diabetes mellitus DM 58 elective PCI 58 heavily pretreated patients 58 coinfected patients 58 curative therapy 58 Stage IIIb 58 BENICAR HCT 58 CTEPH 58 IPAH 58 mg ustekinumab 58 cisplatin gemcitabine 58 NNRTI resistance 58 #mg/m# [002] 58 non valvular atrial 58 bolus dose 58 pegylated interferon alfa 2b 58 Eliquis 58 symptomatic VTE 58 measurable tumor regressions 58 mycophenolate mofetil 58 Myelodysplasia 58 MADRS score 58 pacemaker implantation 58 Cytoxan 58 Group RTOG 58 multicenter placebo controlled 58 unstable angina UA 58 GSK# [001] 58 IV tPA 58 Phase III randomized controlled 58 resectable pancreatic cancer 58 ACTEMRA TM 58 relapsed leukemia 58 Velcade bortezomib 58 radical nephrectomy 58 Naive Patients 58 pyelonephritis 58 nonpsychotic 58 patients evaluable 58 CAMMS# 58 undetectable HCV RNA 58 busulfan 58 CANCIDAS 58 radical prostatectomy RP 58 artery bypass 58 preterm newborns 58 oral antidiabetes 58 SEER registries 58 mesalamine granules 58 TNF antagonist 58 cytogenetic responses 58 Juvenile Idiopathic Arthritis 58 metastatic renal cell carcinoma 58 decitabine 58 hepatic metastases 58 Thal Dex 58 ribavirin RBV 58 psoriatic arthritis PsA 58 cisplatin vinorelbine 58 invasive fungal infection 58 non mutated KRAS 58 leukocyte count 58 plus dexamethasone 58 median CD4 58 bone marrow malignancy 58 genotype 1b 58 adefovir treated 58 LymphoStat B belimumab 58 thromboembolic complications 58 rtPA 58 paclitaxel Taxol R 58 Vidaza azacitidine 58 severe Primary IGFD 58 Pulminiq 58 EDSS scores 58 pegylated liposomal doxorubicin 58 chronic myeloid 58 postoperative complication 58 retinal vein occlusion induced 58 HeFH 58 Zarnestra 58 baseline LDH 58 Onrigin 58 CTAP# Capsules 58 acromegalic patients 58 Systemic Sclerosis 58 thalidomide Thalomid 58 #mg BID [003] 58 HeartMate XVE 58 clinically meaningful improvement 58 undergoing liver transplantation 58 huN# DM1 58 vWD 58 oral hypoglycemic agent 58 bypass graft CABG surgery 58 hemoglobin A1c levels 58 vaginal hysterectomy 58 acute mania 58 hemodynamically significant 58 dirucotide MBP# 58 Decitabine 58 Belldegrun 58 transfusion syndrome 58 glucose intolerant 58 olmesartan 58 radiolabeled TM# 58 XL# administered orally 58 interstitial brachytherapy 58 Gleevec imatinib 58 randomized #:#:# 58 prednisone prednisolone plus 58 mg p = 58 cervical lymph nodes 58 eculizumab therapy 58 doripenem 58 psychiatric outpatients 58 Infusion reactions 58 ascending dose 58 revascularization procedure 58 FLT3 ITD 58 ALT flares 58 Lung transplantation 58 System USRDS 58 allogeneic bone marrow 58 limiting generalizability 58 brivanib 58 salmeterol fluticasone 58 splenectomized 58 Lucrin 58 virus HCV infection 58 cilengitide 58 neoadjuvant treatment 58 Acute Coronary Syndromes ACS 58 QTcF 58 polycythemia vera essential thrombocythemia 58 desvenlafaxine succinate 58 IMPACT DCM 58 Carotid Revascularization Endarterectomy vs. 58 TAXUS VI 58 quetiapine Seroquel 58 OHR/AVR# 58 β blockers 58 #Gy 58 Teriflunomide 58 recovery CRp 58 intravesical therapy 58 aminotransferase levels 58 FLT3 mutations 58 Aflibercept 58 aromatase inhibitor therapy 58 p# MAP kinase inhibitor 58 Phase Ib IIa clinical 58 T2DM 58 colectomy 58 metastatic dermatofibrosarcoma protuberans DFSP 58 seroconverted 58 alemtuzumab treated 58 dexamethasone Decadron 58 levosimendan 58 metastatic CRC 58 liposomal amphotericin B 58 #mmHg [001] 58 VFEND 58 REGENESIS Phase IIb 58 receptor blocker 58 PSMA ADC 58 Allovectin 7 ® 58 cirrhotic 58 chemotherapeutic regimens 58 DAS# CRP 58 autologous SCT 58 miglustat 58 SCIg 58 fibrinolytic therapy 58 HBeAg + 58 PPCM 58 epithelial ovarian 58 Ribavirin causes 58 RLAI 58 severe mitral regurgitation 58 Arzerra ofatumumab 58 preoperative radiotherapy 58 hA# 58 EndoTAGTM 1 58 pyridostigmine 58 drug eluting stent implantation 58 Degarelix 58 chronic idiopathic thrombocytopenic purpura 58 antithrombotic therapy 58 prostate adenocarcinoma 58 R0 resection 58 androgen deprivation 58 low dose cytarabine 58 poor metabolizers 58 FOLFOX4 alone 58 mutated KRAS gene 58 Intervention Effectiveness 58 hematological relapse 58 moderately emetogenic 58 LV dysfunction 58 mcg dose 58 nicardipine 58 unresectable malignant mesothelioma UMM 58 rehospitalized 58 multicenter Phase II 58 Fontan procedure 58 refractory NSCLC 58 5 Fluorouracil 58 docetaxel prednisone 58 polyp recurrence 58 Atypical Hemolytic Uremic Syndrome 58 chemoembolization 58 mecasermin 58 Baseline characteristics 58 transarterial 58 multicenter phase 57 lymphocyte count 57 IR Cysteamine 57 NHANES III 57 syngeneic 57 Sudhir Agrawal D.Phil 57 adenotonsillectomy 57 primary hyperparathyroidism 57 intra articular injection 57 hyperphenylalaninemia HPA due 57 HBeAg positive 57 KRAS wild 57 Breslow thickness 57 Relapsed Refractory Multiple Myeloma 57 ug dose 57 clazosentan 57 HYVET 57 ORMD 57 diabetic kidney 57 Arranon 57 stable angina 57 phase III isavuconazole 57 ipsilateral stroke 57 nonsmall cell lung cancer 57 VaD 57 pmol liter 57 randomized multicenter Phase III 57 oblimersen 57 multiple myeloma MM 57 monoinfected patients 57 mcg doses 57 maximally tolerated lipid lowering 57 corifollitropin alfa 57 IV metastatic melanoma 57 locoregional 57 NSABP B 57 nonvertebral fracture 57 R entecavir 57 dietary questionnaires 57 generalized edema 57 IV malignant melanoma 57 RhuDex R 57 ulcer healing 57 drank pomegranate juice 57 DHEA supplementation 57 Stage IIB 57 oral prednisone 57 drug belatacept 57 kidney pancreas transplant 57 normotensive 57 superficial bladder cancer 57 ® lenalidomide 57 insulin glulisine 57 TKI therapy 57 transplant ASCT 57 coronary revascularization 57 OMP #R# 57 prostate cancer CaP 57 mm ³ 57 leukemia ALL 57 evaluating MGCD# [002] 57 untreated multiple myeloma 57 attain statistical significance 57 HCV infected 57 mm Hg diastolic 57 thymectomy 57 diagnosed GBM 57 peritoneal cancer 57 dexmedetomidine 57 antidiabetic medication 57 transplanted islets 57 Postoperatively 57 MabCampath 57 davunetide intranasal AL 57 achieved PASI 57 hematological parameters 57 cholinesterase inhibitor 57 QD dosing 57 myelofibrosis MF 57 thymoma 57 unfractionated heparin UFH 57 cytogenic 57 seropositive patients 57 urocortin 2 57 basal bolus therapy 57 vasopressor 57 prostate cancer CRPC 57 blinded placebo controlled 57 Adjunctive 57 HBeAg 57 late onset Pompe 57 spinal metastases 57 tumors GIST 57 SNT-MC#/idebenone 57 timepoint 57 Kaplan Meier analysis 57 Stent thrombosis 57 μg dose 57 bilateral orchiectomy 57 silent ischemia 57 Patients Receiving 57 neoadjuvant 57 virologically 57 5 fluorouracil leucovorin 57 ADCS CGIC 57 evaluable 57 warfarin therapy 57 nondiabetic subjects 57 pancreatic neuroendocrine tumors 57 briakinumab 57 euthymic patients 57 neoadjuvant radiation 57 advanced hepatocellular carcinoma 57 pCR 57 â ‰ ¥ 57 pancreatic insufficiency 57 receiving prophylactic anticoagulation 57 cinacalcet 57 Alequel 57 divalproex sodium 57 coinfected 57 OPCAB 57 RhuDex ™ 57 beta carotene supplementation 57 uremic pruritus 57 ONGLYZA saxagliptin 57 oxycodone CR 57 cilostazol 57 esophageal resection 57 recurrent venous thromboembolism 57 nonischemic cardiomyopathy 57 pegaptanib 57 letrozole Femara 57 FIRMAGON 57 chronic renal insufficiency 57 placebo controlled clinical trials 57 ritonavir boosted 57 serum lipid levels 57 tumor histology 57 NYHA Class II 57 retinal vein occlusion 57 heterozygous familial hypercholesterolemia 57 peg interferon 57 oral anticoagulation 57 blastic phase 57 CIMZIA ™ 57 randomized Phase IIb 57 KRAS mutations 57 mg/m2/day 57 chronic ITP patients 57 clomipramine 57 relapsed multiple myeloma 57 AGHD 57 4mg/kg 57 mg qd 57 localized renal 57 lymphoid malignancies 57 noninvasive outpatient 57 candidemia 57 recurrent NSCLC 57 SSc 57 saline placebo 57 preserved ejection fraction 57 Non inferiority 57 J Clin Oncol 57 Circulating tumor cells 57 Operative mortality 57 colorectal adenoma 57 palliative radiotherapy 57 mg TID 57 Hormone Refractory Prostate Cancer 57 proliferative retinopathy 57 comorbid illnesses 57 extracapsular extension 57 humanized interleukin 6 57 aldosterone antagonists 57 unresectable liver cancer 57 surgical debulking 57 PREZISTA r arm 57 aneurysmal subarachnoid hemorrhage 57 androgen suppression 57 neovascular form 57 mcg QD 57 RECIST criteria 57 anemia hemoglobin 57 ICD therapy